NCT00131066

Long-Term Follow-Up Study of Psoriasis Patients

Long-Term Safety Follow-Up Study of Psoriasis Patients Who Have Received MEDI-507

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term safety and profile of psoriasis patients who have completed participation in a previous study and who received treatment with MEDI-507.

Detailed description

This study will evaluate the long-term safety and lymphocyte repletion profile of psoriasis patients who have completed participation in a previous study and who received treatment with MEDI-507. Patients must have had an ALC \> 30% lower than baseline (defined as baseline prior to any MEDI-507 exposure); or an absolute CD4 count of \< 250 cells/uL. This study will also evaluate the development and durability of anti-MEDI-507 antibodies.

Conditions

• Psoriasis

Interventions

Type	Name	Description
OTHER	Follow up from previous treatment with MEDI-507	There will be no investigational drugs administered under this protocol.

Timeline

• Start date: 2002-08-01
• Primary completion: 2003-10-01
• Completion: 2007-12-01
• First posted: 2005-08-17
• Last updated: 2008-09-22

Locations

21 sites across 6 countries: United States, Belgium, Canada, France, Germany, Netherlands